Crossmark

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response

Crossref DOI link: https://doi.org/10.1038/bjc.2017.402

Published Online: 2017-11-21

Published Print: 2018-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lamarca, Angela

Barriuso, Jorge

Kulke, Matthew

Borbath, Ivan

Lenz, Heinz-Josef

Raoul, Jean Luc

Meropol, Neal J

Lombard-Bohas, Catherine

Posey, James

Faivre, Sandrine

Raymond, Eric

Valle, Juan W
License Information

Text and Data Mining valid from 2017-11-21
More Information

Article History

Received: 10 June 2017

Revised: 9 October 2017

Accepted: 12 October 2017

First Online: 21 November 2017

Competing interests

: Angela Lamarca has received Travel and Educational Grants from Pfizer; she has also participated in Speakers' Bureaus for Pfizer. Jorge Barriuso has received Travel Grants, and Research funding from Pfizer, he has also participated in Speakers' Bureaus for Pfizer. Juan W Valle has participated in Consulting or Advisory Role and Speakers' Bureaus for Pfizer. Eric Raymond has received Consulting and Research Grants from Pfizer.

Document is current

Any future updates will be listed below